Key clinical point: Eosinophil-guided therapy for COPD is noninferior to standard therapy.
Major finding: Patients on eosinophil-guided therapy for COPD had half as many days of corticosteroid use as patients on standard therapy.
Study details: Multicenter, randomized, controlled, open-label, noninferiority trial of 318 patients with COPD.
Disclosures: The study was supported by the Danish Regions Medical Fund and the Danish Council for Independent Research. Two authors declared personal fees from pharmaceutical companies outside the submitted work. No other conflicts were declared.
Sivapalan P et al. Lancet Respir Med. 2019, May 20. doi: 10.1016/S2213-2600(19)30176-6.